Results 21 to 30 of about 126,024 (329)

Combined Treatment with MEK and mTOR Inhibitors is Effective in In Vitro and In Vivo Models of Hepatocellular Carcinoma. [PDF]

, 2019
Background: Hepatocellular carcinoma (HCC) is the most common primary liver cancer histotype, characterized by high biological aggressiveness and scarce treatment options.
Calvisi, Diego F, Che, Li, Chen, Xin, Evert, Matthias, Hu, Junjie, Liu, Xianqiong, Lu, Xinjun, Song, Xinhua, Su, Tao, Utpatel, Kirsten, Wang, Jingxiao, Wang, Pan, Xu, Meng, Zhang, Jie, Zhang, Yi   +14 more
core   +1 more source

Hepatocellular carcinoma and multidrug resistance: Past, present and new challenges for therapy improvement [PDF]

, 2015
Hepatocellular carcinoma (HCC) is the most common malignancy of the liver and the third cause of cancer death worldwide. Chronic hepatitis due to HBV and HCV infection are two major risk factors for HCC worldwide.
Cuestas, María Luján, Mathet, Veronica Lidia, Oubiña, Jose Raul   +2 more
core   +1 more source

Epigenetic regulation of ferroptosis via ETS1/miR-23a-3p/ACSL4 axis mediates sorafenib resistance in human hepatocellular carcinoma

Journal of experimental & clinical cancer research : CR, 2022
Background Drug resistance to sorafenib greatly limited the benefits of treatment in patients with hepatocellular carcinoma (HCC). MicroRNAs (miRNAs) participate in the development of drug resistance.
Yuanjun Lu, Y. Chan, H. Tan, Cheng Zhang, W. Guo, Yu Xu, Rakesh Sharma, Zhe-Sheng Chen, Yi Zheng, Ning Wang, Yibin Feng   +10 more
semanticscholar   +1 more source

SC-2001 Overcomes STAT3-mediated Sorafenib Resistance through RFX-1/SHP-1 Activation in Hepatocellular Carcinoma

Neoplasia: An International Journal for Oncology Research, 2014
Hepatocellular carcinoma is the fifth most common solid cancer worldwide. Sorafenib, a small multikinase inhibitor, is the only approved therapy for advanced HCC.
Jung-Chen Su, Ping-Hui Tseng, Szu-Hsien Wu, Cheng-Yi Hsu, Wei-Tien Tai, Yong-Shi Li, I-Ting Chen, Chun-Yu Liu, Kuen-Feng Chen, Chung-Wai Shiau   +9 more
doaj   +1 more source

Anti-proliferative but not anti-angiogenic tyrosine kinase inhibitors enrich for cancer stem cells in soft tissue sarcoma. [PDF]

, 2014
BackgroundIncreasing studies implicate cancer stem cells (CSCs) as the source of resistance and relapse following conventional cytotoxic therapies. Few studies have examined the response of CSCs to targeted therapies, such as tyrosine kinase inhibitors ...
Ames, Erik, Borys, Dariusz, Canter, Robert J, Chen, Mingyi, Grossenbacher, Steven K, Li, Chin-Shang, Mac, Stephanie, Monjazeb, Arta M, Murphy, William J, Sayers, Thomas J, Smith, Rachel C, Tellez, Joe   +11 more
core   +2 more sources

Loss of histone macroH2A1 in hepatocellular carcinoma cells promotes paracrine-mediated chemoresistance and CD4+CD25+FoxP3+ regulatory T cells activation [PDF]

, 2020
Rationale: Loss of histone macroH2A1 induces appearance of cancer stem cells (CSCs)-like cells in hepatocellular carcinoma (HCC). How CSCs interact with the tumor microenvironment and the adaptive immune system is unclear. Methods: We screened aggressive
Drovakova A., Giallongo S., Li Volti G., Lo Re O., Mazza T., Rappa F., Roskams T., Sanna P., Tsochatzis E., Van Haele M., Vinciguerra M., Vinh Luong T.   +11 more
core   +1 more source

Inactivation of Transcriptional Repressor Capicua Confers Sorafenib Resistance in Human Hepatocellular CarcinomaSummary

Cellular and Molecular Gastroenterology and Hepatology, 2020
Background & Aims: Sorafenib is a multireceptor tyrosine kinase inhibitor that can prolong overall survival in patients with advanced hepatocellular carcinoma (HCC). Although most HCC patients who receive sorafenib ultimately show disease progression,
Tomomi Hashiba, Taro Yamashita, Hikari Okada, Kouki Nio, Takehiro Hayashi, Yoshiro Asahina, Tomoyuki Hayashi, Takeshi Terashima, Noriho Iida, Hajime Takatori, Tetsuro Shimakami, Kazunori Kawaguchi, Kuniaki Arai, Yoshio Sakai, Tatsuya Yamashita, Eishiro Mizukoshi, Hiroyuki Takamura, Tetsuo Ohta, Masao Honda, Shuichi Kaneko   +19 more
doaj   +1 more source

Hepatitis B virus induces sorafenib resistance in liver cancer via upregulation of cIAP2 expression

Infectious Agents and Cancer, 2021
Background HBV promotes cell survival by upregulating the expression of the cellular inhibitor of apoptosis protein 2 (cIAP2), however whether it is involved in HBV-induced sorafenib resistance in liver cancer remains unclear.
Shouhua Zhang, Nuoya Li, Yanling Sheng, Wen Chen, Qiangliang Ma, Xin Yu, Jianping Lian, Junquan Zeng, Yipeng Yang, Jinlong Yan   +9 more
doaj   +1 more source

Knockdown of lncRNA TP53TG1 Enhances the Efficacy of Sorafenib in Human Hepatocellular Carcinoma Cells

Non-Coding RNA, 2022
The multikinase inhibitor, sorafenib, is a first-line treatment for hepatocellular carcinoma (HCC), but its limited efficacy, drug resistance and toxicity are a concern.
Qingchun Lu, Mingyang Xin, Qian Guo, Brad S. Rothberg, Ana M. Gamero, Ling Yang   +5 more
doaj   +1 more source

Sorafenib dose escalation is not uniformly associated with blood pressure elevations in normotensive patients with advanced malignancies. [PDF]

, 2014
Hypertension after treatment with vascular endothelial growth factor (VEGF) receptor inhibitors is associated with superior treatment outcomes for advanced cancer patients.
Bakris, GL, Cohen, EEW, Fleming, GF, House, LK, Karovic, S, Karrison, TG, Levine, MR, Maitland, ML, Ratain, MJ, Rudek, MA, Thomeas, V, Wen, Y, Wright, JJ, Wu, K   +13 more
core   +2 more sources